CRSP

CRISPR Therapeutics AG

50.07

USD

+1.51

+3.11%

Nov 06, 15:59 UTC -5

Closed

After-Market

49.77

-0.30

-0.59%

CRISPR Therapeutics AG (CRSP) Earnings

CRSP Earnings Reports

Positive Surprise Ratio

CRSP beat 21 of 40 last estimates.

53%

Next Report

Date of Next Report

Feb 10, 2027

Estimate for Q4 26 (Revenue/ EPS)

$11.54M

-$1.12

Implied change from Q3 26 (Revenue/ EPS)

Implied change from Q4 25 (Revenue/ EPS)

+1235.87%

-18.25%

CRISPR Therapeutics AG earnings per share and revenue

On Nov 04, 2026, CRSP reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -1.05 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 10.70 million, with a --% difference.

Looking ahead to Q4 26, -- analysts forecast an EPS of -1.12 USD, with revenue projected to reach 11.54 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Celcuity Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.46

Actual

-$1.33

Surprise

+9.05%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Genmab A/S ADS

Report Date

Nov 05, 2026 For Q3 26

Estimate

$3.86

Actual

$5.64

Surprise

+46.11%

Certara, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

$0.09

Actual

$0.09

Surprise

-0.88%

Castle Biosciences, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.37

Actual

-$0.13

Surprise

+65.32%

Corvus Pharmaceuticals, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.20

Actual

-$0.22

Surprise

-7.06%

Ginkgo Bioworks Holdings, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.87

Actual

-$0.64

Surprise

+27.17%

Lexicon Pharmaceuticals, Inc.

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.05

Actual

-$0.03

Surprise

+49.41%

Tectonic Therapeutic, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$1.35

Actual

-$1.08

Surprise

+20.37%

SAB Biotherapeutics, Inc. Common Stock

Report Date

Nov 05, 2026 For Q3 26

Estimate

-$0.27

Actual

-$0.24

Surprise

+12.85%

FAQ

What were CRISPR Therapeutics AG's earnings and revenue for the latest quarter Q3 2026?

For Q3 2026, CRISPR Therapeutics AG reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.

How did the market react to CRISPR Therapeutics AG's Q3 2026 earnings?

The stock price moved -- --, changed from -- before the earnings release to -- the day after.

When is CRISPR Therapeutics AG expected to report next?

The next earning report is scheduled for Feb 10, 2027.

What are the forecasts for CRISPR Therapeutics AG's next earnings report?

Based on -- analysts, CRISPR Therapeutics AG is expected to report EPS of -$1.12 and revenue of $11.54M for Q4 2026.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.